Combination of interferon-alpha and all-trans-retinoic acid as a treatment for maintaining remission in high-risk group patients with acute myeloid leukemia

To evaluate the efficiency of combination of interferon-alpha (INF) and all trans-retinoic acid (ATRA) as a treatment for maintaining remission in high risk group patients with acute myeloid leukemia (AML). Three-day INF + ATRA course was administered every 3 months to 22 patients with AML from high...

Full description

Saved in:
Bibliographic Details
Published inTerapevtic̆eskii arhiv Vol. 73; no. 7; p. 15
Main Authors Parovichnikova, E N, Savchenko, V G, Isaev, V G, Demidova, I A, Ol'shanskaia, Iu V, Lapin, V A, Cherepanova, V V, Rekhtman, G B, Perekatova, T N
Format Journal Article
LanguageRussian
Published Russia (Federation) 2001
Subjects
Acute Disease
Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Drug Therapy, Combination
Female
Humans
Interferon-alpha - administration & dosage
Leukemia, Myeloid - drug therapy
Leukemia, Promyelocytic, Acute - drug therapy
Male
Middle Aged
Recurrence
Remission Induction
Risk Factors
Time Factors
Tretinoin - administration & dosage
Online AccessGet more information

Cover

More Information
Summary:To evaluate the efficiency of combination of interferon-alpha (INF) and all trans-retinoic acid (ATRA) as a treatment for maintaining remission in high risk group patients with acute myeloid leukemia (AML). Three-day INF + ATRA course was administered every 3 months to 22 patients with AML from high risk group (impossibility of drug therapy during the first complete remission, resistant forms of AML, relapses, secondary AML, acute promyelocytic leukemia after attaining molecular remission). INF + ATRA during remission maintained a long first complete remission (median 18 months) in patients with primary AML after small-volume drug therapy, led to long first and second complete remissions (median 12 months) in patients with resistant AML, and induced and maintained molecular remissions in patients with acute promyelocytic leukemia.
ISSN:0040-3660